Lawrence G. Hamann PhD

Lawrence G. Hamann is the Co-founder, President, and Chief Executive Officer at Stealth Mode Startup Biotech, Newark, California, United States. He is prior to assuming the role of Head of Drug Discovery Sciences for Takeda in June 2020, Larry was Corporate VP for Chemistry at Celgene/BMS, where he oversaw medicinal and computational chemistry, biochemistry, structural and chemical biology, and screening. In his 28 years in drug discovery, his teams have advanced 18 molecules into the clinic in oncology, immunology, metabolic diseases, virology, and neurology. Included among these are the anti-diabetic drug ONGLYZA™, the anti-hepatitis-C drug DAKLINZA™, and the RNA splicing modulator branaplam for treating spinal muscular atrophy. Prior to Celgene, he was Executive Director, Global Discovery Chemistry at Novartis, after stints at Bristol-Myers Squibb and Ligand Pharmaceuticals. In August of 2017, he was awarded the American Chemical Society’s Heroes of Chemistry Award. Larry is currently based in Boston.